1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Hahne M, Kataoka T, Schröter M, Hofmann K,
Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE,
et al: APRIL, a new ligand of the tumor necrosis factor family,
stimulates tumor cell growth. J Exp Med. 188:1185–1190. 1998.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Mohr E, Serre K, Manz RA, Cunningham AF,
Khan M, Hardie DL, Bird R and MacLennan IC: Dendritic cells and
monocyte/macrophages that create the IL-6/APRIL-rich lymph node
microenvironments where plasmablasts mature. J Immunol.
182:2113–2123. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Varfolomeev E, Kischkel F, Martin F,
Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Erickson S,
French D, et al: APRIL-deficient mice have normal immune system
development. Mol Cell Biol. 24:997–1006. 2004. View Article : Google Scholar : PubMed/NCBI
|
7
|
Planelles L, Medema JP, Hahne M and
Hardenberg G: The expanding role of APRIL in cancer and immunity.
Curr Mol Med. 8:829–844. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Dillon SR, Gross JA, Ansell SM and Novak
AJ: An APRIL to remember: Novel TNF ligands as therapeutic targets.
Nat Rev Drug Discov. 5:235–246. 2006. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Ware CF: APRIL and BAFF connect
autoimmunity and cancer. J Exp Med. 192:F35–F38. 2000. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hu M, Zhao M, An C, Yang M, Li Q, Zhang Y,
Suetsugu A, Tome Y, Yano S, Fu Y, et al: Real-time imaging of
apoptosis induction of human breast cancer cells by the traditional
Chinese medicinal herb tubeimu. Anticancer Res. 32:2509–2514.
2012.PubMed/NCBI
|
11
|
Park BH, Jung KH, Son MK, Seo JH, Lee HS,
Lee JH and Hong SS: Antitumor activity of Pulsatilla koreana
extract in anaplastic thyroid cancer via apoptosis and
anti-angiogenesis. Mol Med Rep. 7:26–30. 2013.PubMed/NCBI
|
12
|
Cao Z, Liao L, Chen X, Lan L, Hu H, Liu Z,
Chen L, Huang S and Du J: Enhancement of antitumor activity of
low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules
in hepatoma 22 tumor-bearing mice. Integr Cancer Ther. 12:174–181.
2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Cao Z, Lin W, Huang Z, Chen X, Zhao J,
Zheng L, Ye H, Liu Z, Liao L and Du J: Jiedu Xiaozheng Yin, a
Chinese herbal formula, inhibits tumor angiogenesis via
downregulation of VEGF-A and VEGFR-2 expression in vivo and in
vitro. Oncol Rep. 29:1080–1086. 2013.PubMed/NCBI
|
14
|
Chen XZ, Cao ZY, Li JN, Hu HX, Zhang YQ,
Huang YM, Liu ZZ, Hu D, Liao LM and Du J: Ethyl acetate extract
from Jiedu Xiaozheng Yin inhibits the proliferation of human
hepatocellular carcinoma cells by suppressing polycomb gene product
Bmi1 and Wnt/β-catenin signaling. Oncol Rep. 32:2710–2718.
2014.PubMed/NCBI
|
15
|
Cao Z, Lin W, Huang Z, Chen X, Zhao J,
Zheng L, Ye H, Liu Z, Liao L and Du J: Ethyl acetate extraction
from a Chinese herbal formula, Jiedu Xiaozheng Yin, inhibits the
proliferation of hepatocellular carcinoma cells via induction of
G0/G1 phase arrest in vivo and in vitro. Int J Oncol. 42:202–210.
2013.PubMed/NCBI
|
16
|
Chen LW, Lin J, Chen W and Zhang W: Effect
of Chinese herbal medicine on patients with primary hepatic
carcinoma in III stage during perioperational period: A report of
42 cases. Zhongguo Zhong Xi Yi Jie He Za Zhi. 25:832–834. 2005.(In
Chinese). PubMed/NCBI
|
17
|
Han T, Jiao F, Hu H, Yuan C, Wang L, Jin
ZL, Song WF and Wang LW: EZH2 promotes cell migration and invasion
but not alters cell proliferation by suppressing E-cadherin, partly
through association with MALAT-1 in pancreatic cancer. Oncotarget.
7:11194–11207. 2016.PubMed/NCBI
|
18
|
Zhang X, Zhang J, Zhang L, van Dam H and
ten Dijke P: UBE2O negatively regulates TRAF6-mediated NF-κB
activation by inhibiting TRAF6 polyubiquitination. Cell Res.
23:366–377. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Saito S, Murata T, Kanda T, Isomura H,
Narita Y, Sugimoto A, Kawashima D and Tsurumi T: Epstein-Barr virus
deubiquitinase downregulates TRAF6-mediated NF-κB signaling during
productive replication. J Virol. 87:4060–4070. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhong L, Cao F and You Q: Effect of TRAF6
on the biological behavior of human lung adenocarcinoma cell.
Tumour Biol. 34:231–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Inoue J, Gohda J, Akiyama T and Semba K:
NF-kappaB activation in development and progression of cancer.
Cancer Sci. 98:268–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhi X, Tao J, Xiang G, Cao H, Liu Z, Yang
K, Lv C and Ni S: APRIL induces cisplatin resistance in gastric
cancer cells via activation of the NF-κB pathway. Cell Physiol
Biochem. 35:571–585. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Yuan D, Pan Y, Zhang J and Shao C: Role of
nuclear factor-kappaB and P53 in radioadaptive response in Chang
live cells. Mutat Res. 688:66–71. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Li Q, Lai Y, Wang C, Xu G, He Z, Shang X,
Sun Y, Zhang F, Liu L and Huang H: Matrine inhibits the
proliferation, invasion and migration of castration-resistant
prostate cancer cells through regulation of the NF-κB signaling
pathway. Oncol Rep. 35:375–381. 2016.PubMed/NCBI
|
25
|
Chen Y, Lin Y, Li Y and Li C: Total
flavonoids of Hedyotis diffusa Willd inhibit inflammatory responses
in LPS-activated macrophages via suppression of the NF-κB and MAPK
signaling pathways. Exp Ther Med. 11:1116–1122. 2016.PubMed/NCBI
|
26
|
Mackay F and Tangye SG: The role of the
BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr
Opin Pharmacol. 4:347–354. 2004. View Article : Google Scholar : PubMed/NCBI
|
27
|
Klein B, Tarte K, Jourdan M, Mathouk K,
Moreaux J, Jourdan E, Legouffe E, De Vos J and Rossi JF: Survival
and proliferation factors of normal and malignant plasma cells. Int
J Hematol. 78:106–113. 2003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Moreaux J, Legouffe E, Jourdan E, Quittet
P, Rème T, Lugagne C, Moine P, Rossi JF, Klein B and Tarte K: BAFF
and APRIL protect myeloma cells from apoptosis induced by
interleukin 6 deprivation and dexamethasone. Blood. 103:3148–3157.
2004. View Article : Google Scholar : PubMed/NCBI
|
29
|
Moreaux J, Veyrune JL, De Vos J and Klein
B: APRIL is overexpressed in cancer: Link with tumor progression.
BMC Cancer. 9:832009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Wang J, Ding W, Sun B, Jing R, Huang H,
Shi G and Wang H: Targeting of colorectal cancer growth,
metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA.
Mol Cell Biochem. 363:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Jiao F, Hu H, Yuan C and Wang L, Jiang W,
Jin Z, Guo Z and Wang L: Elevated expression level of long
noncoding RNA MALAT-1 facilitates cell growth, migration and
invasion in pancreatic cancer. Oncol Rep. 32:2485–2492.
2014.PubMed/NCBI
|
32
|
Wang F, Chen L, Ni H, Wang G, Ding W, Cong
H, Ju S, Yang S and Wang H: APRIL depletion induces cell cycle
arrest and apoptosis through blocking TGF-β1/ERK signaling pathway
in human colorectal cancer cells. Mol Cell Biochem. 383:179–189.
2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Tao T, Cheng C, Ji Y, Xu G, Zhang J, Zhang
L and Shen A: Numbl inhibits glioma cell migration and invasion by
suppressing TRAF5-mediated NF-κB activation. Mol Biol Cell.
23:2635–2644. 2012. View Article : Google Scholar : PubMed/NCBI
|
34
|
Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ
and Fisher PB: Molecular basis of nuclear factor-kappaB activation
by astrocyte elevated gene-1. Cancer Res. 68:1478–1484. 2008.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Starczynowski DT, Lockwood WW, Deléhouzée
S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL,
et al: TRAF6 is an amplified oncogene bridging the RAS and NF-κB
pathways in human lung cancer. J Clin Invest. 121:4095–4105. 2011.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Ramachandran C, Rodriguez S, Ramachandran
R, Nair PK Raveendran, Fonseca H, Khatib Z, Escalon E and Melnick
SJ: Expression profiles of apoptotic genes induced by curcumin in
human breast cancer and mammary epithelial cell lines. Anticancer
Res. 25:3293–3302. 2005.PubMed/NCBI
|